AHA files brief defending South Dakota’s 340B contract pharmacy law
On May 14, 2025, the American Hospital Association (AHA) filed an amicus brief in the U.S. District Court for the District of South Dakota,...
South Dakota Department of Health hosts webinar on Measles Response
The South Dakota Department of Health invites healthcare professionals to a critical Measles Response Webinar on Thursday, May 22, from 3–4 PM CT. This...
South Dakota Launches Maternal and Infant Health Task Force and Releases New Data to...
The South Dakota Department of Health (DOH) has launched the Maternal and Infant Health Task Force, a statewide initiative to reduce preventable deaths among...
2025 Rural Healthcare Facility Recruitment Assistance Program
The Department of Health (DOH) is excited to announce the availability of the Rural Healthcare Facility Recruitment Assistance Program (RHFRAP) 2025 incentive program. This...
SD PASRR Training on April 24
The SD Preadmission Screening and Resident Review (PASRR) team invites you to join an upcoming webinar focused on foundational PASRR information and how Major...
Quarterly Advocacy Update: Spring 2025
Our Spring update includes a review of the 2025 South Dakota Legislative Session, a preview of the interim session, and a few federal updates....
Hospital Preparedness is a top priority for SDAHO
SDAHO would like to thank the South Dakota Department of Health for their 2025 Public Health Preparedness and Response Conference March 19-20 in Chamberlain....
Ongoing Risk of Dengue Virus Infections and Updated Testing Recommendations in the US
The South Dakota Department of Health (SD-DOH) is asking medical providers to remain vigilant for dengue infection among returning travelers. Dengue virus is not...
2025 South Dakota Legislative Update: Week 9
The 2025 South Dakota Legislative session wrapped up this past Thursday, and overall, it was a good session for healthcare. We’ve seen better sessions,...
2025 South Dakota Legislative Update: Week 8
The biggest hurdle this week for the SDAHO advocacy team, is SB 154: prohibit pharmaceutical manufacturers from interfering in contracts between 340B entities and...
